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ABSTRACT
The use of the methylotrophic yeast, Pichia pastoris, as one of the most effective and 
versatile systems for the expression of heterologous proteins in biopharmaceutical 
manufacturing has become increasingly popular in recent years. The impurity caused 
by residual host cell DNA is one of the major concerns in production of recombinant 
therapeutics. The aim of the present study was to develop a semi-quantitative, multiplex 
PCR method to determine the level of impurity in biopharmaceuticals produced in 
Pichia pastoris as the host. Primers were designed based on the rDNA repeat region and 
optimized to achieve the limit of detection in a multiplex PCR following by analyzing 
with MYImageAnalysis (Thermo Fisher Scientific, USA) software to quantify the 
concentration of Pichia pastoris genomic DNA in pertinent controls and drug samples. 
The multiplex PCR were able to detect up to 1 femtogram (fg) of genomic DNA under 
optimized conditions. Moreover, achieved concentration of DNA in controls and samples 
through relevant standard curve indicates the feasibility of this method in the presence 
of inhibitory effects. In comparison with other methods such as real-time PCR and 
Threshold assay, the assay shows acceptable sensitivity, precision and linearity along with 
ease of use, low equipment costs and analyte flexibility. We thus propose this method to 
be considered as a useful tool to estimate host cell residual DNA in biopharmaceuticals 
produced in Pichia pastoris.
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• The impurity of residual host cell DNA is an important concern in production of biopharmaceuticals.
•	 Pichia pastoris is an effective and versatile system for the expression of recombinant proteins.
• Quantitative Polymerase Chain Reaction could be used for quantifying residual host-cell DNA.
• We designed a sensitive and valid PCR method for detection and quantification of Pichia residual DNA.
Introduction Biopharmaceuticals play a pivotal role in modern medicine. 
Various expression systems have been employed for the 
production of therapeutic proteins. Yeast host systems 
are one of the most widely used approaches for bio-
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manufacturing of recombinant proteins especially those 
that cannot be actively expressed in other host systems 
such as Escherichia coli (E. coli) due to glycosylation 
requirements for proper folding and biological activity 
(Gerngross, 2004; Schmidt, 2004). Pichia pastoris 
(P. pastoris) seems to be the second most frequently 
used yeast strain after Saccharomyces cerevisiae 
(S. cerevisiae) for both basic research projects and 
industrial manufacturing (Macauley-Patrick et al., 2005). 
Compared to S. cerevisiae, P. pastoris shows higher cell 
density cultivation due to its powerful methanol-inducible 
alcohol oxidase1 (AOX1) promoter. It also has a higher 
secretion capability for heterologous proteins (Potvin et 
al., 2012). Other advantages of the P. pastoris system 
over expression systems derived from higher eukaryotes 
such as insect and mammalian tissue culture cell systems 
include higher expression levels, simplicity and speed 
of the protocols and cost effectiveness (Cereghino and 
Cregg, 2000). The US Food and Drug Administration 
(FDA) approved the first recombinant protein produced 
in P. pastoris (Kalbitor® by Dyax Corp.) in 2009 while 
other similar products await the results of clinical trials 
(Walsh, 2010).
All biological products originating from complex 
living systems are mixed with a large number of other 
macromolecules and potential impurities such as residual 
host cell DNA and host cell proteins. Because of safety 
reasons, downstream processing is performed to confirm 
that such impurities are reduced to acceptable levels in 
the final drug product (Lokteff et al., 2001; Forcic et al., 
2005). Since the residual DNA could theoretically induce 
oncogenic events and/or reduce efficacy in recipients of 
the biological products, its quantity determination should 
be considered as an essential part of the product safety 
assessment (Sheng-Fowler et al., 2009; Yang et al., 2010; 
Shen et al., 2013).
In the 1987 World Health Organization (WHO) 
guideline, the maximum accepted amount of total rDNA 
is determined to be 100 picograms per dose, which is 
the cutoff value also used by the FDA . More recently, 
the WHO limit was changed to 10 nanograms per dose, 
which is also required by the European Union (EU) 
(Lebron et al., 2006). There are different approaches for 
quantifying levels of host-cell DNA in biopharmaceutical 
products such as PicoGreen analysis, the Threshold assay, 
hybridization techniques and quantitative Polymerase 
Chain Reaction (qPCR).These methods detect cellular 
DNA based on total DNA or species-specific DNA 
(Durrant et al., 1995; Strachan and Read., 1999). High 
throughput and low cost are the two main advantages of 
the PicoGreen analysis but low sensitivity is the main 
limitation of this technique (Ikeda et al., 2009). 
The Threshold assay suffers from low throughput and 
relatively high cost though it offers a highly sensitive and 
standardized protocol. Lack of sensitivity and relatively 
long testing time are the major drawbacks of hybridization 
techniques, which has reduced their usage in recent years 
(Wang et al., 2012). Recently, PCR based methods, 
specifically real-time PCR, have been widely used for 
the determination of residual DNA in biological and 
biopharmaceutical manufacturing (Nissom, 2007; Lee et 
al., 2010; Cai et al., 2011). In PCR methods amplification 
of a specific sequence in template DNA allows for 
detection of extremely low levels of contaminating DNA 
in less than two hours.
To our knowledge, there is no published data 
on the quantification of host cell residual DNA in 
biopharmaceuticals produced in P. pastoris.  The aim of 
this study is to design a sensitive and valid method for 
detection and quantification of Pichia residual DNA. 
Effectiveness of this method for residual DNA analysis 
on a sample of marketed biopharmaceutical will be 
evaluated. 
Materials and Methods 
Materials 
Pichia pastoris G115 was obtained from Pichia 
Expression Kit (Invitrogen, Thermo Fisher Scientific, 
USA). PrimePrepTM Genomic DNA Isolation Kit was 
purchased from GeNet Bio (Korea) and nuclease-free 
water (Cat No: R0582) was provided from Fermentase 
(Thermo Fisher Scientific, USA). Custom synthetic 
oligonucleotide primers were obtained from SinaClon 
(Iran). PCR Master Mix 2X (Cat No: K0171) was also 
supplied from Thermo Fisher Scientific (USA). 
Preparation of P. pastoris genomic DNA
P. pastoris G115 was grown in YPD liquid media consisted 
of 1% (w/v) yeast extract, 2% (w/v) peptone and 2% (w/v) 
D-glucose in distilled water. Genomic DNA was extracted 
using the PrimePrepTM Genomic DNA Isolation Kit. The 
initial concentration of P. pastoris genomic DNA was 90 
ng/μl. To prepare the DNA standard curve, 10-fold serial 
dilutions of P. pastoris genomic DNA were prepared using 
nuclease-free water  to generate concentrations between 
20 pg/µl and 0.2 fg/µl.
Primer design
Primers targeting the rDNA repeat region from the 
GS115 strain of P. pastoris (GenBank accession number: 
FN392325) were designed using the online software 
program Primer3Plus. The sequences of the amplification 
primers used were 5’-CCCTCCAATTGTTCCTCGT-3’ 
(forward) and 5’-GGGGAATAAGGGTTCGATTC-3’ 
(reverse) for the 18S rDNA region and 
5’-TCGCTATGAACGCTTGACTG-3’ (forward) and 
5’-GGGGCTCATGAAGAACAGAA-3’ (reverse) for the 
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26S rDNA region. These primer sets amplify 189-bp and 
192-bp fragments from the 18srDNA and 26srDNA repeat 
regions, respectively. Custom synthetic oligonucleotide 
primers were obtained from Sigma. 
Determination of optimal annealing temperature, 
concentration and limit of detection for each primer pair
After DNA isolation, gradient PCR reactions were 
performed to determine the optimum annealing 
temperature (program name: A) and concentration 
(program name: B) for each primer pair. The limit of 
detection was subsequently determined for each primer 
pair by performing a PCR reaction using optimized 
conditions with serial dilutions of template DNA (from 
100 pg to 1 fg) (program names: C and D). Tables 1 and 
2 show the thermal cycling conditions and the reaction 
contents for each program. 
Preparation of spiked control, negative controls and 
samples 
To evaluate the efficiency of multiplex PCR in the presence 
of potential inhibitory ingredients from commercial 
recombinant therapeutics, spiked controls were prepared. 
A known amount of P. pastoris genomic DNA was spiked 
into a 1/10 dilution of the recombinant hepatitis B surface 
antigen vaccine, which was made in the host P. pastoris, 
to generate final concentrations of 1, 10 and 100 fg. To 
reduce the inhibitory effects of vaccine ingredients, the 
vaccine was diluted 10-fold. An un-spiked control was 
also analyzed to determine the level of P. pastoris genomic 
DNA already presented in the recombinant hepatitis 
B surface antigen vaccine. In addition, to exclude false 
results from the PCR amplification, a negative control 
was included in each run. The negative control contained 
nuclease-free water in place of the DNA template. All 
spiked, un-spiked and negative controls were prepared in 
duplicate.
Two samples generated in a Saccharomyces cerevisiae 
host were also prepared for testing: recombinant insulin 
and recombinant hepatitis B antigen vaccines. A 
recombinant hepatitis B antigen vaccine produced in the 
yeast Hansenula polymorpha (syn. Pichia angusta) was 
also tested. All samples were diluted 10-fold.
Multiplex	PCR	amplification
Multiplex PCR reactions for triplicate 10-fold serially 
diluted DNA standards, duplicate quality controls, the 
negative control and samples from the hosts described 
above were performed using the E PCR program (Table1).
Quantification	 of	 PCR	 products	 using	 agarose	 gel	
densitometry
Amplified DNA was analyzed using gel electrophoresis 
with a 1% agarose gel. Eight microliters of each sample 
were loaded onto the gel, and the results were visualized 
using a UV transilluminator. The images were saved for 
Table 1. Thermal cycling conditions used for different reactions.
Program names PCR conditions
A 95 ºC for 3 min, 30x [95 ºC for 20 s, 57 ± 7 ºC for 10 s and 72 ºC for 20 s], 72 ºC for 8 min
B, C, D, E 95 ºC for 3 min, 30x [95 ºC for 20 s, 54 ºC for 10 s and 72 ºC for 20 s], 72 ºC for 8 min
Table 2. Reaction contents for each program used in this study.
Program* genomic DNA stock concentration (5 μL)
Forward / Reverse primer stock 
concentration (2 μL) Types of Primers
A 20 pg/μL 20 μM 26srRNA or 18srRNA forward and reverse primer
B 20 pg/μL 5,10,15,20 μM 26srRNA or 18srRNA forward and reverse primer
C 20, 2, 0.2, 0.02, 0.002, 0.0002 pg/μL 5 μM 26srRNA forward and reverse primer
D 20, 2, 0.2, 0.02, 0.002, 0.0002 pg/μL 5 μM 18srRNA forward and reverse primer
E 20, 2, 0.2, 0.02, 0.002, 0.0002 pg/μL 5 μM 18srRNA and 26srRNA forward and reverse primer
* 12.5 μL of PCR Master Mix (2X) and 5.5 μL of nuclease free water were added to each reactions. Final reaction volume was 25 μL.
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further analysis.
The intensity of the bands was analyzed using MY 
Image Analysis Software, version 1.1 (Thermo Fisher 
Scientific). A standard curve was subsequently generated 
by plotting the log of the primary template DNA amount 
against the density of the corresponding band, i.e., mean 
intensity per pixel. The residual DNA concentration of 
the samples and the spiked controls was estimated by 
comparing the band intensity to the standard curve.
Results
Primer	efficiency	and	process	optimization
Gradient PCRs demonstrated that selecting the minimum 
primer concentration (5 μM) and an annealing temperature 
of 54°C for both primer pairs would maximize the 
amplification of products and minimize primer dimer 
formation, resulting in the highest limit of detection for 
residual DNA.
PCR reactions were performed to determine the limit 
of detection for each primer pair. The results indicated that 
the 18s rRNA and 26s rRNA primer pairs could amplify P. 
pastoris genomic DNA at the amount of 1 pg and 100 fg 
respectively (Data not shown).
Multiplex PCR assay and data analysis 
Multiplex PCR using serially diluted genomic DNA 
indicated that the amplification of P. pastoris genomic 
DNA was enhanced by approximately 100 times when 
two efficient primers were used together, facilitating the 
detection of genomic DNA at a concentration of 1 fg (Fig. 1). 
The P. pastoris genomic DNA standard curve displayed 
a positive correlation between primary template DNA 
concentration and band density (Fig. 2). The concentration 
of DNA in the spiked controls and the un-spiked control 
(i.e., the sample from the recombinant hepatitis B antigen 
vaccine produced in a P. pastoris host) was determined 
using the standard curve (Table 3) (Fig. 3). The band 
density of the spiked controls was higher than that of the 
corresponding standard DNA, likely due to the presence 
of residual DNA in the vaccine sample, which indicates 
Table 3. Density of DNA standards, spikes and sample product bands.
Concentration of template 
DNA(fg)
Mean density of product band
(intensity/pixel)
Concentration of template 
DNA(fg)
Mean density of product band 
(intensity/pixel) and
DNA standard 100 pg                     66959 DNA spike 100 fg                   72253
DNA standard 10 pg                       61513 DNA spike 10 fg                   65002
DNA standard 1 pg                       52296 DNA spike 1 fg                   61692
DNA standard 100 fg                       49403 Sample(vaccine produced in P. pasroris)     34043
DNA standard 10 fg                       42242
DNA standard 1 fg                       37582
Figure. 1. Multiplex PCR assay of serially diluted genomic DNA (L: Ladder, 1: 100 pg genomic DNA, 2: 10 pg genomic DNA, 3: 1 pg genomic 
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no inhibitory effect due to the 10-fold dilution of the 
vaccine.After analyzing the primers using the NCBI blast 
program, it was observed that these primers could also 
amplify a 192-bp fragment from the rDNA repeat region 
of S. cerevisiae, which is also used as an expression host. 
The efficacy of this system for the amplification 
of S. cerevisae was evaluated. Although the genome 
sequence of H. polymorpha has not yet been 
published, it is expected that these primer sets could 
also amplify a similar fragment from this yeast 
(Fig. 4).
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Discussion 
This study was performed to develop a method for the 
detection of residual DNA from the host P. pastoris in 
biopharmaceuticals. A desirable sensitivity level for 
the detection of residual DNA was achieved using the 
following strategies: 1) designing two sets of primers 
that both efficiently amplify a similar size fragment from 
the rDNA repeat region, and 2) developing a detection 
method that uses a multiplex PCR assay. Since the 
difference between the amplified fragment sizes is not 
Figure. 4. Multiplex PCR assay of samples produced by other 
hosts (L: Ladder, 1: recombinant insulin, 2: recombinant hepatitis B 
antigen produced in S. cerevisiae, 3: recombinant hepatitis B antigen 
produced in H. polymorpha).
Figure. 3. Multiplex PCR assay of spiked controls and un-spiked 
control sample (  L: Ladder, S: sample, S1: 1 fg spike, S2:  10 fg 
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distinguishable on agarose gel electrophoresis, using these 
two sets of primers led to achieve increased sensitivity. In 
addition, choosing suitable image analysis software for 
calculating the intensity of amplified bands could make the 
results sufficiently accurate and sensitive for this method 
to become a standard method for determining whether to 
accept or reject a lot or batch of biopharmaceuticals.
In some cases, sensitivity can be increased by using a 
target with a higher copy number, such as a sequence from 
a repeat region within the genome. However, high copy 
number sequences, such as transposon elements, are less 
stable in the genome and may undergo significant changes 
in copy number. This instability could obscure the data 
concerning the presence of residual DNA if the target 
copy number changed during production (Lovatt, 2002). 
In addition, target genes with higher copy number do not 
provide the highest measurement or reveal the largest 
clearance of residual host cell DNA from purified samples. 
These findings suggest that different DNA sequences may 
be cleared or degraded at different rates and highlight 
unexpected factors that must be considered when choosing 
a PCR gene target for QPCR assays (Verardo et al., 2012). 
In light of these findings, we focused on the rDNA repeat 
region, which does not change copy number as frequently 
as high copy number transposing elements but meets the 
sensitivity requirements for this type of analysis.
Although real-time PCR quantifies DNA more 
precisely than the method presented here (Nissom, 2007), 
the aim of residual DNA detection is to determine whether 
the residual DNA in a dose of recombinant therapeutic is 
below the permissible limits set by regulatory guidelines. 
Thus, the exact amount of residual DNA doesn’t 
necessarily seem to be quantified. In addition, the cost of 
analysis can be significant and should be considered when 
evaluating an assay. 
The price per sample analysis in the multiplex PCR 
method is much lower than that of quantitative real-
time PCR, which could improve cost management when 
manufacturing biopharmaceuticals. Besides, ease of 
execution, robustness and good enough sensitivity are 
additional advantages of this method.
The detection of a similar product from other yeasts 
suggests that these primer sets could also be used to 
test for the presence of residual DNA from other yeast 
hosts, including S. cerevisiae and H. polymorpha. 
Although this could reduce the specificity of the test, it 
also provides a high-throughput system for analyzing 
the residual DNA of all yeast hosts with a universal 
primer set. However, a little more carefulness may 
be required to prevent possible contamination and 
false results could effectively be excluded by running 
negative controls. It is also worth noting that while the 
same primer set can be used for multiple hosts, each 
host requires its own genomic DNA standard curve for 
quantification. 
Conclusion
In conclusion, this work presents a convenient and 
reliable method for detecting residual P. pastoris DNA 
in purified protein samples. This study provides a low-
cost and sensitive alternative screening tool for assessing 
the batches quality control of purified protein samples. 
However, it would be recommended to analyze the size of 
residual P. pastoris DNA in addition to its quantity.
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